Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10637/12598
Título : Impact of SARS-CoV-2 infection on patients with cancer : retrospective and transversal studies in Spanish population
Autor : Garde Noguera, Javier.
Fernández Murga, María Leonor.
Giner Bosch, Vicent.
Domínguez Márquez, Ma. Victoria.
García Sánchez, José.
Soler Cataluña, Juan José.
Materias: Cáncer - Quimioterapia.Cáncer - Pacientes.Coronavirus.Coronaviruses.Cancer - Immunotherapy.Cancer - Chemotherapy.COVID-19 - España.COVID-19 (Disease) - Spain.Cancer - Patients.Cáncer - Inmunoterapia.SARS-CoV-2 (Virus)
Fecha de publicación : 25-nov-2020
Editorial : MDPI
Citación : Garde-Noguera, J., Fernández-Murga, M.L., Giner-Bosch, V., Dominguez-Márquez, V., Sánchez, J.G., Soler-Cataluña, J.J. et al. (2020). Impact of SARS-CoV-2 infection on patients with cancer: retrospective and transversal studies in Spanish population. Cancers, vol. 12, i. 12 (25 nov.), art. 3513. DOI: https://doi.org/10.3390/cancers12123513
Resumen : Background: Studies of patients with cancer a ected by coronavirus disease 2019 (COVID-19) are needed to assess the impact of the disease in this sensitive population, and the influence of di erent cancer treatments on the COVID-19 infection and seroconversion. Material and Methods: We performed a retrospective analysis of all patients hospitalized with RT-PCR positive for COVID-19 in our region to assess the prevalence of cancer patients and describe their characteristics and evolution (Cohort 1). Concurrently, a transversal study was carried out in patients on active systemic cancer treatment for symptomatology and seroprevalence (IgG/IgM by ELISA-method) against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (Cohort 2). Results: A total of 215 patients (Cohort 1) were admitted to hospital with a confirmed COVID-19 infection between February 28 and April 30, 2020, and 17 died (7.9%). A medical record of cancer was noted in 43 cases (20%), 6 of them required Intensive care unit ICU attention (14%), and 7 died (16%). There were thirty-six patients (83%) who tested IgG/IgM positive for SARS-CoV-2. Patients on immunosuppressive therapies presented a lower ratio of seroconversion (40% vs. 8%; p = 0.02). In Cohort 2, 166 patients were included in a symptoms-survey and tested for SARS-CoV-2. Any type of potential COVID-19-related symptom was referred up to 67.4% of patients (85.9% vs. 48.2% vs. 73.9%, for patients on chemotherapy, immunotherapy and targeted therapies respectively, p < 0.05). The seroprevalence ratio was 1.8% for the whole cohort with no significant di erences by patient or treatment characteristics. Conclusion: Patients with cancer present higher risks for hospital needs for COVID-19 infection. The lack of SARS-CoV-2 seroconversion may be a concern for patients on immunosuppressive therapies. Patients receiving systematic therapies relayed a high rate of potentially COVID-19-related symptoms, particularly those receiving chemotherapy. However, the seroconversion rate remains low and in the range of general population.
Descripción : Este artículo se encuentra disponible en la siguiente URL: https://www.mdpi.com/2072-6694/12/12/3513
En este artículo también participan: Franscica López Chuliá, Beatriz Honrubia, Nuria Piera y Antonio Llombart-Cussac.
URI : http://hdl.handle.net/10637/12598
Derechos: http://creativecommons.org/licenses/by/4.0/deed.es
ISSN : 2072-6694 (Electrónico).
Aparece en las colecciones: Dpto. Medicina y Cirugía

Ficheros en este ítem:
Fichero Tamaño Formato  
Impact_Garde_CANCERS_2020.pdf730,81 kBAdobe PDFVisualizar/Abrir

Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.